- Home
- ADTN vs ERAS Comparison
ADTN vs ERAS Comparison
Compare ADTN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADTN
- ERAS
- Stock Information
- Founded
- ADTN 1985
- ERAS 2018
- Country
- ADTN United States
- ERAS United States
- Employees
- ADTN N/A
- ERAS N/A
- Industry
- ADTN Telecommunications Equipment
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ADTN Telecommunications
- ERAS Health Care
- Exchange
- ADTN Nasdaq
- ERAS Nasdaq
- Market Cap
- ADTN 656.7M
- ERAS 723.8M
- IPO Year
- ADTN 1994
- ERAS 2021
- Fundamental
- Price
- ADTN $8.19
- ERAS $2.54
- Analyst Decision
- ADTN Strong Buy
- ERAS Strong Buy
- Analyst Count
- ADTN 3
- ERAS 5
- Target Price
- ADTN $10.33
- ERAS $5.90
- AVG Volume (30 Days)
- ADTN 624.3K
- ERAS 1.5M
- Earning Date
- ADTN 11-06-2024
- ERAS 11-12-2024
- Dividend Yield
- ADTN N/A
- ERAS N/A
- EPS Growth
- ADTN N/A
- ERAS N/A
- EPS
- ADTN N/A
- ERAS N/A
- Revenue
- ADTN $905,347,000.00
- ERAS N/A
- Revenue This Year
- ADTN N/A
- ERAS N/A
- Revenue Next Year
- ADTN $10.32
- ERAS N/A
- P/E Ratio
- ADTN N/A
- ERAS N/A
- Revenue Growth
- ADTN N/A
- ERAS N/A
- 52 Week Low
- ADTN $4.34
- ERAS $1.64
- 52 Week High
- ADTN $9.21
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- ADTN 50.25
- ERAS 41.70
- Support Level
- ADTN $8.03
- ERAS $2.51
- Resistance Level
- ADTN $8.87
- ERAS $2.68
- Average True Range (ATR)
- ADTN 0.39
- ERAS 0.19
- MACD
- ADTN -0.12
- ERAS -0.05
- Stochastic Oscillator
- ADTN 13.56
- ERAS 17.39
About ADTN ADTRAN Holdings Inc.
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support Segment which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.